Summary
This filing is an amendment (8-K/A) to a previously filed 8-K by Bristol-Myers Squibb Company (BMY), dated April 26, 2007. The amendment, filed on May 31, 2007, revises supplemental financial information that was initially provided. This updated information pertains to the first quarter of 2007 and includes more detailed data on net sales, inventory levels ('months on hand'), and estimated product demand for key segments including International Pharmaceutical, Nutritionals, and Other Health Care. For investors, the primary significance of this amendment lies in the refined data provided for net sales, inventory, and demand. This granular information, presented for various reporting segments and historical periods (as of December 31, 2005, March 31, 2006, December 31, 2006, and March 31, 2007), offers a clearer picture of the company's performance trends and operational efficiency. Investors can use this data to better assess product performance, supply chain management, and the underlying demand for BMY's products.
Key Highlights
- 1Amendment to a previous 8-K filing to revise supplemental financial data.
- 2The revision focuses on Q1 2007 results and related supplemental information.
- 3Includes updated net sales data for key reporting segments.
- 4Provides 'months on hand' (inventory) information for key products and segments.
- 5Incorporates estimated demand information for key products and growth drivers.
- 6Supplemental data covers multiple historical periods for comparative analysis (as of Dec 31, 2005, Mar 31, 2006, Dec 31, 2006, and Mar 31, 2007).
- 7The revised supplemental information is provided as Exhibit 99.2.